Trial
NCT03063203
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
Janssen Pharmaceuticals; National Institutes of Health (NIH); National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia
Intervention
Decitabine
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-02